Eupraxia Pharmaceuticals Prices $55 Million Public Offering

MT Newswires Live

Feb 20

Eupraxia Pharmaceuticals (EPRX) said Thursday it priced a public offering of about 6.4 million shares at $7 per share and pre-funded warrants to purchase roughly 1.4 million shares at $6.99999 per warrant, for gross proceeds of approximately $55 million.

Each pre-funded warrant entitles the holder to purchase one common share at an exercise price of CA$0.00001 ($0.0000073) per share and will not expire until exercised in full. The company granted underwriters a 30-day option to purchase up to 1,178,571 additional common shares on the same terms.

The offering is expected to close on Feb. 20.

Eupraxia said it plans to use the net proceeds primarily to advance EP-104GI for Eosinophilic Esophagitis. A portion will also support additional gastrointestinal indications, research and development, business development and general corporate purposes.

Shares of the company were down more than 4% in recent trading.

Price: 7.81, Change: -0.35, Percent Change: -4.29

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2612628082"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612628082\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612628082?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 04:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612628082","market":"hk","top_or_hot":-1,"title":"Eupraxia Pharmaceuticals Prices $55 Million Public Offering","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/EPRX\">Eupraxia Pharmaceuticals</a> (EPRX) said Thursday it priced a public offering of about 6.4 million shares at $7 per share and pre-funded warrants to purchase roughly 1.4 million shares at $6.99999 per warrant, for gross proceeds of approximately $55 million.</p><p>Each pre-funded warrant entitles the holder to purchase one common share at an exercise price of CA$0.00001 ($0.0000073) per share and will not expire until exercised in full. The company granted underwriters a 30-day option to purchase up to 1,178,571 additional common shares on the same terms.</p><p>The offering is expected to close on Feb. 20.</p><p>Eupraxia said it plans to use the net proceeds primarily to advance EP-104GI for Eosinophilic Esophagitis. A portion will also support additional gastrointestinal indications, research and development, business development and general corporate purposes.</p><p>Shares of the company were down more than 4% in recent trading.</p><p>Price: 7.81, Change: -0.35, Percent Change: -4.29</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eupraxia Pharmaceuticals Prices $55 Million Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEupraxia Pharmaceuticals Prices $55 Million Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-20 04:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/EPRX\">Eupraxia Pharmaceuticals</a> (EPRX) said Thursday it priced a public offering of about 6.4 million shares at $7 per share and pre-funded warrants to purchase roughly 1.4 million shares at $6.99999 per warrant, for gross proceeds of approximately $55 million.</p><p>Each pre-funded warrant entitles the holder to purchase one common share at an exercise price of CA$0.00001 ($0.0000073) per share and will not expire until exercised in full. The company granted underwriters a 30-day option to purchase up to 1,178,571 additional common shares on the same terms.</p><p>The offering is expected to close on Feb. 20.</p><p>Eupraxia said it plans to use the net proceeds primarily to advance EP-104GI for Eosinophilic Esophagitis. A portion will also support additional gastrointestinal indications, research and development, business development and general corporate purposes.</p><p>Shares of the company were down more than 4% in recent trading.</p><p>Price: 7.81, Change: -0.35, Percent Change: -4.29</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EPRX","symbol_name":"Eupraxia Pharmaceuticals","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2612628082","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612628082","pubTimestamp":1771531566,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Eupraxia Pharmaceuticals  said Thursday it priced a public offering of about 6.4 million shares at $7 per share and pre-funded warrants to purchase roughly 1.4 million shares at $6.99999 per warrant, for gross proceeds of approximately $55 million.Each pre-funded warrant entitles the holder to purchase one common share at an exercise price of CA$0.00001  per share and will not expire until exercised in full. The company granted underwriters a 30-day option to purchase up to 1,178,571 additional common shares on the same terms.The offering is expected to close on Feb. 20.Eupraxia said it plans to use the net proceeds primarily to advance EP-104GI for Eosinophilic Esophagitis. A portion will also support additional gastrointestinal indications, research and development, business development and general corporate purposes.Shares of the company were down more than 4% in recent trading.Price: 7.81, Change: -0.35, Percent Change: -4.29","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EPRX":"Eupraxia Pharmaceuticals","BK4139":"生物科技"},"translate_title":"Eupraxia Pharmaceuticals公开发行定价5500万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPRX":1.5},"content_text":"Eupraxia Pharmaceuticals (EPRX) said Thursday it priced a public offering of about 6.4 million shares at $7 per share and pre-funded warrants to purchase roughly 1.4 million shares at $6.99999 per warrant, for gross proceeds of approximately $55 million.Each pre-funded warrant entitles the holder to purchase one common share at an exercise price of CA$0.00001 ($0.0000073) per share and will not expire until exercised in full. The company granted underwriters a 30-day option to purchase up to 1,178,571 additional common shares on the same terms.The offering is expected to close on Feb. 20.Eupraxia said it plans to use the net proceeds primarily to advance EP-104GI for Eosinophilic Esophagitis. A portion will also support additional gastrointestinal indications, research and development, business development and general corporate purposes.Shares of the company were down more than 4% in recent trading.Price: 7.81, Change: -0.35, Percent Change: -4.29","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}